ADAMTS13 and thrombotic thrombocytopenic purpura: While in congenital TTP it is probably sufficient to monitor plasma infusion efficiency by platelet and hemoglobin measurement only, in acquired TTP there is a benefit in monitoring the PEX efficacy by measuring the ADAMTS-13 activity and anti-ADAMTS-13 antibody levels.74–76